Space Peptides specializes in providing services for the research, development, and production of polypeptide drugs. [Photo/WeChat account: txfabu]
The semaglutide active pharmaceutical ingredient manufactured by Space Peptides, located in the Taixing Economic Development Zone, Taixing, Jiangsu province, has successfully obtained a Drug Master File (DMF) from the U.S. Food and Drug Administration.
This is the first active pharmaceutical ingredient variety of the company to receive a DMF filing and marks the product having obtained the passport to enter the global mainstream market.
The company, with a total investment of over 1 billion yuan ($147.6 million), specializes in providing services for the R&D and production of polypeptide drugs. It possesses capabilities ranging from new drug discovery and process development to GMP (Good Manufacturing Practice) production and global registration and commercialization.
The biomedical industry is one of the key industrial chains in Taixing's modern industrial system. It has been steadily strengthening in recent years across sub-sectors such as active pharmaceutical ingredients and preparations.